Repligen Corporation completes its acquisition of BioLife Solutions, adding key biopreservation media assets and expanding its global footprint in the cell therapy workflow market.
BioLife Solutions has been acquired by Repligen, resulting in the delisting of its shares as it becomes a part of the larger bioprocessing entity. Under the terms of the transaction, BioLife stockholders received a combination of $11.25 in cash and 0.1442 shares of Repligen common stock per share held.
Stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock.
The portfolio, including CryoStor, will be integrated into Repligen's broader bioprocessing offering.
Repligen has officially completed its acquisition of BioLife Solutions, a strategic move designed to bolster its presence in the cell and gene therapy market. By integrating BioLife's high-margin consumables and biopreservation media portfolio, Repligen aims to enhance its bioprocessing offerings and leverage expanded global distribution channels.
It adds a high-margin, recurring revenue business and expands Repligen's presence in the cell therapy workflow.
The company intends to provide details during its third quarter 2026 earnings call.
Repligen Corporation has finalized its acquisition of BioLife Solutions, integrating a specialized portfolio of cell processing tools into its bioprocessing business. The deal, which provides BioLife stockholders with $11.25 in cash and 0.1442 shares of Repligen stock per share, aims to bolster Repligen's presence in the high-margin cell and gene therapy market.
The acquisition allows Repligen to expand its presence in the cell therapy market by adding BioLife's high-margin, deeply embedded consumables and biopreservation media to its existing bioprocessing technology suite.